⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4991448 | 0.69 | — | — | |
| SCHEMBL3325785 | 0.64 | — | — | |
| SCHEMBL82843 | 0.64 | — | — | |
| Hydrochloric Acid SCHEMBL28369527 | 0.63 | — | — | |
| Bromide SCHEMBL27835668 | 0.63 | — | — | |
| SCHEMBL19759482 | 0.61 | — | — | |
| SCHEMBL5834889 | 0.60 | — | — | |
| SCHEMBL9407451 | 0.60 | — | — | |
| SCHEMBL7761503 | 0.60 | — | — | |
| SCHEMBL4796797 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142145-A1 | COMBINATIONS COMPRISING A DIPEPTIDYLPEPTIDASE - IV INHIBITOR | BALKAN BORK (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130122008-A1 | Anti-IL 1- ß Antibody Combination Therapy | NOVARTIS AG | 2013-05-16 | — | — | US | disclosed |
| EP-2427209-A1 | ANTI-IL1- ANTIBODY COMBINATION THERAPY | Novartis AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-1248604-B2 | COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-20110301172-A1 | COMBINATION OF DPP-IV INHIBITOR, PPAR ANTIDIABETIC AND METMORFORMIN | BURKEY BRYAN (US) | 2011-12-08 | — | — | US | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
| WO-2010128092-A1 | ANTI-IL1-β ANTIBODY COMBINATION THERAPY | NOVARTIS AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-7754725-B2 | Dihydroxyphenyl isoindolymethanones | ASTEX THERAPEUTICS LTD. (GB) | 2010-07-13 | — | — | US | disclosed |
| US-20100076084-A1 | Method of Treating Metabolic Disorders, Especially Diabetes, or a Disease or Condition Associated with Diabetes | GATLIN MARJORIE REGAN | 2010-03-25 | — | — | US | disclosed |
| WO-2006084757-A2 | COMBINATION OF CA/MG SALT OF VALSARTAN WITH AN ANTIDIABETIC AGENT | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| US-20050124663-A1 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | GATLIN MARJORIE R (US) | 2005-06-09 | — | — | US | disclosed |
| US-6878749-B2 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | disclosed |
| US-20030162816-A1 | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes | GATLIN MARJORIE REGAN (US) | 2003-08-28 | — | — | US | disclosed |
| US-20030139434-A1 | Combinations comprising dipeptidylpeptidase-iv inhibitor | BALKAN BORK (US) | 2003-07-24 | — | — | US | disclosed |
| US-6559188-B1 | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes | NOVARTIS AG (CH) | 2003-05-06 | — | — | US | disclosed |
| EP-1248604-A2 | COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | Novartis AG (CH) | 2002-10-16 | — | — | EP | disclosed |
| EP-1212077-A2 | PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND ANOTHER ANTIDIABETIC AGENT | Novartis AG (CH) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001052825-A2 | COMBINATIONS COMPRISING DIPEPTIDYLPEPTIDASE-IV INHIBITORS AND ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| WO-2001021159-A2 | PHARMACEUTICAL COMPOSITION OF NATEGLINIDE AND ANOTHER ANTIDIABETCAGENT | NOVARTIS AG (CH) | 2001-03-29 | — | — | WO | disclosed |